Kristine Pelton

Kristine Pelton

Auto-generated profile, based on publicly available information

Kristine Pelton

Brown University Center for Alzheimer’s Disease Research

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2017 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
STShyam K. Tanguturi
Shyam K. Tanguturi
LTlorenzo trippa
lorenzo trippa
SRShakti H. Ramkissoon
Shakti H. Ramkissoon
KPKristine Pelton
Kristine Pelton
DKDavid Knoff
David Knoff
BABrian M. Alexander
Brian M. Alexander
Biomarkers can improve clinical trial efficiency, but designing and interpreting biomarker-driven trials require knowledge of relationships among biomarkers, clinical covariates, and endpoints. We investigated these relationships across genomic subgroups of glioblastoma (GBM) within our institution (DF/BWCC), validated results in The Cancer Genome Atlas (TCGA), and demonstrated potential impacts on clinical trial design and interpretation. We identified genotyped patients at DF/BWCC, and clinical associations across 4 common GBM genomic biomarker groups were compared along with overall survival (OS), progression-free survival (PFS), and survival post-progression (SPP). Significant associations were validated in TCGA. Biomarker-based clinical trials were simulated using various assumptions. Epidermal growth factor receptor (EGFR)(+) and p53(−) subgroups were more likely isocitrate dehydrogenase (IDH) wild-type. Phosphatidylinositol-3 kinase (PI3K)(+) patients were older, and patients with O6-DNA methylguanine-methyltransferase (MGMT)–promoter methylation were more often female. OS, PFS, and SPP were all longer for IDH mutant and MGMT methylated patients, but there was no independent prognostic value for other genomic subgroups. PI3K(+) patients had shorter PFS among IDH wild-type tumors, however, and no DF/BWCC long-term survivors were either EGFR(+) (0% vs 7%, P = .014) or p53(−) (0% vs 10%, P = .005). The degree of biomarker overlap impacted the efficiency of Bayesian-adaptive clinical trials, while PFS and OS distribution variation had less impact. Biomarker frequency was proportionally associated with sample size in all designs. We identified several associations between GBM genomic subgroups and clinical or molecular prognostic covariates and validated known prognostic factors in all survival periods. These results are important for biomarker-based trial design and interpretation of biomarker-only and nonrandomized trials.

13 February 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ABAnne-Florence Blandin
Anne-Florence Blandin
RGRoss Giglio
Ross Giglio
MGMaya Graham
Maya Graham
GGGuadalupe Garcia
Guadalupe Garcia
SMSeth Malinowski
Seth Malinowski
KLKeith L. Ligon
Keith L. Ligon
Purpose: Anaplastic lymphoma kinase (ALK) aberrations have been identified in pediatric-type infant gliomas, but their occurrence across age groups, functional effects, and treatment response has not been broadly established. Experimental Design: We performed a comprehensive analysis of ALK expression and genomic aberrations in both newly generated and retrospective data from 371 glioblastomas (156 adult, 205 infant/pediatric, and 10 congenital) with in vitro and in vivo validation of aberrations. Results: ALK aberrations at the protein or genomic level were detected in 12% of gliomas (45/371) in a wide age range (0–80 years). Recurrent as well as novel ALK fusions (LRRFIP1–ALK, DCTN1–ALK, PRKD3–ALK) were present in 50% (5/10) of congenital/infant, 1.4% (3/205) of pediatric, and 1.9% (3/156) of adult GBMs. ALK fusions were present as the only candidate driver in congenital/infant GBMs and were sometimes focally amplified. In contrast, adult ALK fusions co-occurred with other oncogenic drivers. No activating ALK mutations were identified in any age group. Novel and recurrent ALK rearrangements promoted STAT3 and ERK1/2 pathways and transformation in vitro and in vivo. ALK-fused GBM cellular and mouse models were responsive to ALK inhibitors, including in patient cells derived from a congenital GBM. Relevant to the treatment of infant gliomas, we showed that ALK protein appears minimally expressed in the forebrain at perinatal stages, and no gross effects on perinatal brain development were seen in pregnant mice treated with the ALK inhibitor ceritinib. Conclusions: These findings support use of brain-penetrant ALK inhibitors in clinical trials across infant, pediatric, and adult GBMs. See related commentary by Mack and Bertrand, p. 2567

28 February 2024 in medRxiv
Verified
Preprint
Open access
PDF file
ASA. Campbell Sullivan
A. Campbell Sullivan
GZGabrielle Zuniga
Gabrielle Zuniga
PRPaulino Ramirez
Paulino Ramirez
RFRoman Fernandez
Roman Fernandez
CWChen-Pin Wang
Chen-Pin Wang
BFBess Frost
Bess Frost
Retrotransposons are viral-like DNA sequences that constitute approximately 41% of the human genome. Studies in Drosophila, mice, cultured cells, and human brain indicate that retrotransposons are activated in settings of tauopathy, including Alzheimer’s disease, and causally drive neurodegeneration. The anti-retroviral medication 3TC (lamivudine), a nucleoside analog reverse transcriptase inhibitor, limits retrotransposon activation and suppresses neurodegeneration in tau transgenic Drosophila, two mouse models of tauopathy, and in brain assembloids derived from patients with sporadic Alzheimer’s disease. We performed a 24-week phase 2a open-label clinical trial of 300 mg daily oral 3TC ( NCT04552795 ) in 12 participants aged 52-83 years with a diagnosis of mild cognitive impairment due to suspected Alzheimer’s disease. Primary outcomes included feasibility, blood brain barrier penetration, effects of 3TC on reverse transcriptase activity in the periphery, and safety. Secondary outcomes included changes in cognition and fluid-based biomarkers of neurodegeneration and neuroinflammation. All participants completed the six-month trial; one event of gastrointestinal bleeding due to a peptic ulcer was reported. 3TC was detected in blood and cerebrospinal fluid (CSF) of all participants, suggestive of adherence to study drug and effective brain penetration. Cognitive measures remained stable throughout the study. Glial fibrillary acidic protein (GFAP) ( P =0.03) and Flt1 ( P =0.05) were significantly reduced in CSF over the treatment period; Aβ42/40 ( P =0.009) and IL-15 ( P =0.006) were significantly elevated in plasma. While this is an open label study of small sample size, the significant decrease of some neurodegeneration- and neuroinflammation-related biomarkers in CSF, significantly elevated levels of plasma Aβ42/40, and a trending decrease of CSF NfL after six months of 3TC exposure suggest a beneficial effect on subjects with mild cognitive impairment due to suspected Alzheimer’s disease. Feasibility, safety, tolerability, and central nervous system (CNS) penetration assessments further support clinical evaluation of 3TC in a larger placebo-controlled, multi-dose clinical trial.

17 August 2022 in The American Journal of Pathology
Verified
Journal Article
Closed access
GLGeorge Lambrinos
George Lambrinos
VCVivian Cristofaro
Vivian Cristofaro
KPKristine Pelton
Kristine Pelton
ABAlexander Bigger-Allen
Alexander Bigger-Allen
CDClaire Doyle
Claire Doyle
RARosalyn Adam
Rosalyn Adam

25 November 2025
Verified
Other
Open access
ABAnne-Florence Blandin
Anne-Florence Blandin
RGRoss Giglio
Ross Giglio
MGMaya Graham
Maya Graham
GGGuadalupe Garcia
Guadalupe Garcia
SMSeth Malinowski
Seth Malinowski
KLKeith L. Ligon
Keith L. Ligon
Supplementary Figure 2: T1 post-contrast axial and sagittal images of ALK-fused and non ALK-altered GBMs and ALK staining in ALK-fused congenital GBMs. A. Example images from patients with ALK aberrations (76, 89, 116, 197)B. In contrast to those without ALK aberrations (right columns). Contrast is gadolinium for those where applicable and show enhancement within both the tumor categories.C. Representative H&E and ALK IHCs of congenital GBM harboring an ALK fusion.

25 November 2025
Verified
Other
Open access
ABAnne-Florence Blandin
Anne-Florence Blandin
RGRoss Giglio
Ross Giglio
MGMaya Graham
Maya Graham
GGGuadalupe Garcia
Guadalupe Garcia
SMSeth Malinowski
Seth Malinowski
KLKeith L. Ligon
Keith L. Ligon
Additional information tables 1 to 8.